Mucosal chemokine adjuvant enhances synDNA vaccine-mediated responses to SARS-CoV-2 and provides heterologous protection in vivo
E. Gary, Nicholas J. Tursi, Bryce M. Warner, Elizabeth M. Parzych, Ali Ali, Drew Frase, Estella Moffat, Carissa Embury‐Hyatt, Trevor R.F. Smith, Kate E. Broderick, Laurent Humeau, Darwyn Kobasa, Ami Patel, Daniel W. Kulp, David B. Weiner
Abstract
T cells in the respiratory mucosa. pCTACK co-immunization confers 100% protection from heterologous Delta VOC challenge. This study shows that mucosal chemokine adjuvants can direct vaccine-induced responses to specific immunological sites and have significant effects on heterologous challenge. Further study of this unique chemokine-adjuvanted vaccine approach in the context of SARS-CoV-2 vaccines is likely important.
Topics & Concepts
HeterologousAdjuvantIn vivoChemokineVirologyImmunologyMedicineBiologyImmune systemBiotechnologyGeneGeneticsSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesAnimal Virus Infections Studies